Pharmexa receives US patent on the GV1001 vaccine for chemotherapy
The US patent authorities have issued a patent to Pharmexa on the GV1001 vaccine. GV1001 is Pharmexa's peptide vaccine targeting telomerase, which is currently under preparation for Phase III trials in pancreatic cancer. Pharmexa already has issued and validated patents for the GV1001 vaccine in Europe and Australia.
Pharmexa's issued patent claims cover specific peptides, including the GV1001 vaccine, and their use in cancer immunotherapy. In addition, divisional patent applications have been filed in both Europe and the USA.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.